DOCSLIB.ORG

NHS Dictionary of Medicines and Devices (Dm+D) Editorial Policy Release 2.0 Version 3.5 July 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NHS Dictionary of Medicines and Devices (Dm+D) Editorial Policy Release 2.0 Version 3.5 July 2020 NHS dictionary of medicines and devices (dm+d) Editorial policy Release 2.0 Version 3.5 July 2020 This document is produced and maintained by NHS Prescription Services (provided by NHS Business Services Authority) in partnership with NHS Digital. The dm+d NHS Medicines Standard is approved by the Data Coordination Board. Document control since 2016 Date NHS dm+d Change summary Issued May 2016 Release 2.0 Appendix II VMP Prescribing Status – order of information in this section Version 3.2 changed for clarity. Appendix II Controlled Drug Prescribing Information included reference to: Ketamine having changed to Schedule 2 (CD) status on 30/11/2015 Temazepam having changed status to Schedule 3 (CD no register) on 1/06/2015 Appendix II Examples of SNF Patterns – Strength expression and Appendix XIV Injections and Infusions sections - inclusion of mannitol as an example of where dual representation is applied Appendix V VMP Form table updated Addition of Appendix XX VMP and AMP Strength Description Differences providing examples of strength mismatches and reasons. May 2017 Release 2.0 dm+d – the NHS Medicines Standard. Section reworded with updated Version 3.3 information regarding the Standardisation Committee for Care Information (SCCI) standard. SCCI logo added to front page too. HSCIC name change to NHS Digital throughout dm+d enquiries/issues – link added for diagram representation online Appendix II: • Virtual Medicinal Product Name: minor updates • New subsection – reference to the inhaled delivered dose in a VMP description • New subsection – reference to the British Pharmacopoeia (‘BP’) in a VMP description • Actual Medicinal Product Note: updating the policy for generic AMPs listed by wholesalers • Actual Medicinal Product Pack Note: adding clarity to discontinued packs and the supply chain • Strength expression – inclusion of trichloroacetic acid as an example where dual expression is used Appendix V VMP Form table updated Appendix VI VMP Route table updated Appendix XI Abbreviations – minor updates and table updated of products unable to be abbreviated to 60 characters or less Appendix XX VMP and AMP Strength Description Differences – inclusion of the variation of eye product strengths in the transition of SmPC regulated product name descriptions. Addition of Appendix XXI British Pharmacopoeia (‘BP’) reference in a Virtual Medicinal Product (VMP) description includes a decision tree that demonstrates the decision making process for whether or not to include the suffix BP in the VMP name Addition of Appendix XXII Medical Devices that may be prescribed in NHS dm+d: Editorial policy (Release 2.0 V.3.5) (07/2020) 2 Secondary Care explaining the policy about authoring of these products Addition of Appendix XXIII Representation of diluents for Special Order cytotoxic infusions – SACT (Systemic Anti-Cancer Therapies) Glossary of terms – minor updates December Release 2.0 Appendix II VTM Name. Note added following safety concerns about 2018 Version 3.4 prescribing / dispensing of Peppermint Oil and Peppermint water Appendix II VMP Prescribing Status text updates following the consultation November 2016. Appendix II VMP Basis of Strength Substance (BoSS). Inclusion of parenteral dexamethasone products authored to include reference to base in brackets following safety concerns. Appendix II Semantic Normal Form Patterns used in NHS dm+d. Note added clarifying dm+d authoring style of expression per ml / per 5ml for oral solutions and oral suspensions. Appendix II Schedule 1 and ACBS Indicators. Note added that flags updated in line with the ‘gluten-free’ update to the NHS (General Medical Services Contracts) (Prescription of Drugs etc.) (Amendment) Regulations 2018 (effective from 4th December 2018). Appendix V and Appendix VI VMP Forms and Routes tables updated New Appendix XXIII added on Radiopharmaceuticals Addition of Appendix XXV Authoring of Biosimilar Systemic Anticancer Therapy (SACT) dose banded SACT products July 2020 Release 2.0 dm+d – the NHS Medicines Standard. Reference to responsibility for Version 3.5 Information Standards transferring to the Data Coordination Board. Inclusion of the email address for enquiries specifically concerning secondary care: [email protected] Appendix II VTM and VMP word order. Clarification that the source manufacturer SmPC documentation now tends to guide the dm+d editorial style rather than the BNF. Appendix II VMP Prescribing Status minor text updates to the tense following the implementation of the changes March 2016. Appendix II Controlled Drug Prescribing Information included reference to: Gabapentin and pregabalin changing status to Schedule 3 (CD no reg, exempt safe custody). Appendix II Restrictions on Availability. Individual patient supply, Sandimmun capsules and oral solution removed as an example. Appendix V VMP Forms table updated (including a form of ‘Herbal material’ to support authoring of cannabis based products for medicinal use [CBMP]). Appendix VI VMP Route table updated. Appendix VII Units of Measure updated. Appendix IX AMP Flavours table updated. Appendix XVIII Global Trade Item Numbers. Text updated to read more clearly. A caveat added to support the dm+d user community. Appendix XXV Authoring of SACT dose banded products. Section updated to included editorial policy on authoring of products with a strength equal to or over 1g/1000mg. NHS dm+d: Editorial policy (Release 2.0 V.3.5) (07/2020) 3 Contents NHS dictionary of medicines and devices (dm+d) .......................................................... 1 NHS dictionary of medicines and devices and its governance structure ......................... 6 Appendix I ....................................................................................................................... 8 UKCPRS Programme .................................................................................................. 8 Background to primary care drug dictionary (NHS dm+drelease 1.0) ......................... 9 Appendix II .................................................................................................................... 11 Fields and sources for identifiers and other attributes ............................................... 11 Virtual Therapeutic Moiety ..................................................................................... 11 Virtual Medicinal Product ....................................................................................... 14 Actual Medicinal Product ....................................................................................... 33 Virtual Medicinal Product Pack .............................................................................. 43 Actual Medicinal Product Pack .............................................................................. 47 Other data .............................................................................................................. 57 Semantic Normal Form Patterns used in NHS dm+d ............................................ 61 EXAMPLES OF SNF PATTERNS – Strength expression ......................................... 62 Appendix III ................................................................................................................... 70 List A — Virtual Medicinal Product Reason For Name Change ................................ 70 Appendix IV .................................................................................................................. 71 List B — Virtual Medicinal Product Combined Route and Form ................................ 71 Appendix V ................................................................................................................... 79 List C – Virtual Medicinal Product Form .................................................................... 79 Appendix VI ................................................................................................................ 106 List D – Virtual Medicinal Product Route ................................................................. 106 Appendix VII ............................................................................................................... 109 List E – Units of Measure ........................................................................................ 109 Appendix VIII .............................................................................................................. 114 List F 1 – ActualMedicinal Product Manufacturer .................................................... 114 Appendix IX ................................................................................................................ 115 List G – ActualMedicinal Product Flavours .............................................................. 115 Appendix X ................................................................................................................. 117 List H – Actual Medicinal Product Excipients .......................................................... 117 Appendix XI ................................................................................................................ 122 List I – Abbreviated name (for label name only) at VMP & AMP level ..................... 122 NHS dm+d: Editorial policy (Release 2.0 V.3.5) (07/2020) 4 Appendix XII ............................................................................................................... 134 Homeopathic Preparations ...................................................................................... 134 Appendix XIII .............................................................................................................
Load more

Recommended publications
  • By in Vivo's Biopharma, Medtech and Diagnostics Teams
    invivo.pharmaintelligence.informa.com JANUARY 2018 Invol. 36 ❚ no. 01 Vivopharma intelligence ❚ informa 2018 OUTLOOK By In Vivo’s Biopharma, Medtech and Diagnostics Teams PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ In Vivo Pharma intelligence | January 2018 BIOPHARMA MEDTECH 2018 DIAGNOSTICS OUTLOOK 12 22 28 Biopharma 2018: Medtech 2018: Diagnostics 2018: Is There Still A Place For Pharma The Place For Innovation Steady Progress And In The New Health Care As Value-based Health Care The Big Get Bigger Economy? Gains Momentum MARK RATNER WILLIAM LOONEY ASHLEY YEO If the beginning of 2017 was marked 2018 will be a time of transition in health 2017 was a watershed year in many by doubts around whether and how care, when biopharma’s counterparts respects, politically, economically the FDA would act with respect to in adjacent industry segments scale up and commercially for many players complex diagnostics, we enter 2018 in a radical redesign of their traditional in the medtech field. Where will the feeling that slow-moving vessel may business models. Biopharma is not opportunities lie in 2018? Will finally be turning. moving as quickly, and it confronts a breakthrough medtech innovation still strategic dilemma on how to address the have a place among providers often prospect of a much more powerful set of riding on fumes when it comes to 36 rivals in the ongoing battle to own the budgets, and is it all as bad as some patient experience in medicine. would make out? Thirty-five Years Covering Health Care: The More Things Change… 30 PETER CHARLISH A Virtuous Cycle: What The The health care industry has come a Immuno-Oncology Revolution long way in the past 35 years, although Means For Other Disease Areas in some areas very little has changed.
    [Show full text]
  • Appendix 1 Definitions of Words and Phrases Used in the Act And
    Appendix 1 Definitions of Words and Phrases Used in the Act and Subordinate Legislation The persons responsible for drafting a piece of legislation aim to achieve clarity and avoid ambiguity in the document. However, most words have shades of meaning and the interpretation of the statute or instrument becomes difficult for those who have to obey or enforce it, especially when such persons are not law­ yers. In the last analysis, it is a judge who has to decide whether a particular set of circumstances fall within or outside a given set of words, but this may be too late for the citizen who may have done utmost to keep within the law. It should, however, be pointed out that government departments and others who have a duty to enforce a piece of legislation are usually willing to advise members of the public as to its meaning and effects. In order to help those who have to obey or enforce the law an 'interpretation' section, regulation or rule containing a number of technical terms used in the document is often included. In the Medicines Act, sections 130,131 and 132 are devoted to this purpose. However, many other terms are defined in other sec­ tions and are sometimes less easy to locate. Furthermore, numerous statutory instruments also define various words and phrases and these definitions are not always identical with those used in the Act. To facilitate reference to these defi­ nitions, they have been collected together and printed alphabetically with the exception of 'medicinal product' and 'wholesale' and 'retail' sale which, in view of their importance, are treated separately.
    [Show full text]
  • Therapeutic Consequences of the Drug Lag 93 X Recent Developments, 1972 to 1974 ...•
    REGULATION AND DRUG DEVELOPMENT William M. Wardell and Louis Lasagna American Enterprise Institute for Public Policy Research Washington. D. C. CONTENTS INTRODUCTION .. ................... 1 PART ONE Science. Government, and the Current State of Affairs I PRE-1962 PRACTICES: THE EVOLUTION OF CON- TROLS OVER THERAPEUTIC DRUGS 5 II POST-1962 GUIDELINES AND PRACTICES 19 III THE NATURE OF EVIDENCE 27 IV WEIGHING THE EVIDENCE 37 V ECONOMICS AND DRUG DEVELOPMENT 45 PART TWO Lessons from Other Countries VI APPROACHES TO INTERNATIONAL COMPARISONS 51 VII PATTERNS OF INTRODUCTION OF NEW DRUGS IN BRITAIN AND THE UNITED STATES 55 VIII BRITISH USAGE AND AMERICAN AWARENESS OF SOME NEW DRUGS 79 IX THERAPEUTIC CONSEQUENCES OF THE DRUG LAG 93 X RECENT DEVELOPMENTS, 1972 TO 1974 ...•....... 109 PART THREE The Wider Issues XI THE INTENT OF CONGRESS AND THE NEEDS OF PATIENTS 127 XII THE RUBRICS REEXAMINED 135 XIII SUGGESTIONS FOR IMPROVEMENT. ............. .. 143 XIV CONCLUSIONS.................................... 161 APPENDIX: Definition of "Substantial Evidence" 167 NOTES 171 INTRODUCTION In the late 1950s the Congress of the United States began holding subcommittee hearings on various matters pertaining to the pharma­ ceutical industry. Two of the most vigorous and sensational were those chaired by Congressman Blatnik and by Senator Kefauver. They were highly critical of the quality of drug advertising, theevi­ dence for effectiveness of marketed pharmaceuticals, the allegedly monopolistic nature of the drug industry, and the price of medicines. The drug industry, accustomed to respect and gratitude from physicians and the public, was suddenly confronted with hostile, sensational newspaper headlines and stories and a rising wave of angry criticism.
    [Show full text]
  • An Expert System for Development of Powder Filled Hard Gelatin Capsule Formulations
    An Expert System For Development of Powder Filled Hard Gelatin Capsule Formulations Thesis submitted to the University of London Faculty of Medicine for THE DEGREE OF DOCTOR OF PHILOSOPHY ky Samantha Miu Ha Lai B.Pharm., M.R.Pharm.S. September 1996 The School of Pharmacy University of London Brunswick Square London WCIN lAX ProQuest Number: 10104253 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10104253 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Dedicated to my Father ACKNOWLEDGMENT I would like to dedicate this thesis to my father, without whom I would not be able to achieve this PhD. My sister, Esther and my boyfriend, Eric were also very understanding and have been most supportive throughout my ‘ups and downs’. The guidance and supervision provided by my supervisor. Professor J M Newton and also by Dr F Podczeck also made this PhD possible. Special thanks must go to Professor Newton for being so incredibly patient and spending so much time with me on top of his busy schedule.
    [Show full text]
  • International Nonproprietary Names (Inns) to Medicines
    WWW.CIOMS.CH Special Newsletter | 29 August 2018 This is the first of a series of special newsletters describing the work of CIOMS member organizations and partners. It describes the programme within the World Health Organization (WHO) that assigns International Nonproprietary Names (INNs) to medicines. The WHO INN Programme: International Nonproprietary Names for pharmaceutical substances With tens of thousands of medicines on the market, confusion between Medicine names: a safety issue medicine names can have serious consequences for patient safety. How INNs are defined WHO assigns single, unique, globally accepted names to INNs – a map to medicines classes pharmaceutical substances. The International Nonproprietary Names The INN MedNet (INN) nomenclature provides a common language for people all over The School of INN (SoINN) the world—including the CIOMS Working Groups—to work together for INNs for better medicines use the safe and effective use of medicines. Medicine names: a safety issue This variety of names can cause confusion, which A medicine can be identified in different ways: by its might lead to medication errors. brand name (“Aspirin”) or its chemical name Patient safety is a primary concern of WHO. In (acetylsalicylic acid). Furthermore, historically some 1950 the Organization established the INN regulatory authorities have approved nonproprietary Programme for pharmaceutical substances to names for pharmaceuticals in their jurisdictions (e.g., mitigate the risk of name confusions and medication paracetamol in Europe, acetaminophen in the US). errors. The main objective of the programme is to A brand name can designate a medicine containing define a single, unique, globally accepted name for more than one active substance, and often the same each pharmaceutical substance.
    [Show full text]
  • 204200Orig1s000 204200Orig2s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204200Orig1s000 204200Orig2s000 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 204-200 and 204-640 Priority or Standard Standard Submit Date(s) March 7, 2012 Received Date(s) March 7, 2012 PDUFA Goal Date January 7, 2013 Division / Office DPARP/OND Reviewer Name(s) Peter Starke, MD Review Completion Date October 29, 2012 Established Name Epinephrine injection, USP, 1mg/mL (Proposed) Trade Name Adrenalin® Therapeutic Class Catecholamine Applicant JHP Pharmaceuticals, LLC Formulation(s) Solution for injection Proposed Dosing Hypersensitivity reactions: IM or SC Regimen injection(b) (4) [Ophthalmic use: Topical irrigation or intraocular bolus injection] Proposed Indication(s) Hypersensitivity reactions: severe acute anaphylactic reactions, (b) (4) [Ophthalmic use: induction and maintenance of mydriasis during cataract surgery] Intended Population(s) Hypersensitivity reactions: No age restrictions [Ophthalmic use: No age restrictions] Reference ID: 3209828 Clinical Review ● Peter Starke, MD NDA 204-200 ● Adrenalin® (epinephrine) MEDICAL OFFICER REVIEW Division of Pulmonary, Allergy and Rheumatology Products (DPARP) SUBMISSIONS REVIEWED IN THIS DOCUMENT Document Date CDER Stamp Date Submission Comments March 7, 2012 March 7, 2012 SD-1, eCTD-0000 New NDA submission April 9, 2012 April 9, 2012 SD-2, eCTD-0001 PREA waiver request – Anaphylaxis April 9, 2012 April 9, 2012 SD-3, eCTD-0002 PREA waiver request – Mydriasis April 18, 2012 April 18, 2012 SD-4, eCTD-0003 Request for proprietary name review Sept 5, 2012 Sept 6, 2012 SD-22, eCTD-0021 Draft Ophthalmic Labeling Oct 22, 2012 Oct 22, 2012 SD-27, eCDT-0026 Certification that EpiPen is the reference for the 505(b)(2) application RECOMMENDED REGULATORY ACTION NDA/SUPPLEMENTS: X APPROVAL COMPLETE RESPONSE OTHER ACTION: 2 Reference ID: 3209828 Clinical Review ● Peter Starke, MD NDA 204-200 ● Adrenalin® (epinephrine) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ........................................
    [Show full text]
  • Drug Discovery: a History
    ________________________________________________________________________________________________________________________ ______________________________ Drug Discovery A History Walter Sneader School of Pharmacy University of Strathclyde, Glasgow, UK ________________________________________________________________________________________________________________________ ______________________________ Drug Discovery ________________________________________________________________________________________________________________________ ______________________________ Drug Discovery A History Walter Sneader School of Pharmacy University of Strathclyde, Glasgow, UK Copyright u 2005 John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England Telephone (+44) 1243 779777 Email (for orders and customer service enquiries): [email protected] All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, or emailed to [email protected], or faxed to (+44) 1243
    [Show full text]
  • Pharmaceutical Advertising 2017
    ICLGThe International Comparative Legal Guide to: Pharmaceutical Advertising 2017 14th Edition A practical cross-border insight into pharmaceutical advertising Published by Global Legal Group, with contributions from: Allen & Gledhill LLP Jones Day ALRUD Jusmedico Advokatanpartsselskab Arnold & Porter Kaye Scholer LLP Kyriakides Georgopoulos Law Firm Arthur Cox LCH Law Compliance Health Baker & McKenzie Life Sciences Legal Biolato Longo Ridola & Mori Mannheimer Swartling Advokatbyrå Clayton Utz Nishimura & Asahi Clifford Chance Norton Rose Fulbright Canada LLP Cuatrecasas OLIVARES Deep & Far Attorneys-at-Law Pestalozzi Attorneys at Law Gorodissky & Partners (Ukraine) Quinz Gün + Partners Roschier, Attorneys Ltd. Haavind Sołtysiński Kawecki & Szlęzak Herbst Kinsky Rechtsanwälte GmbH Subramaniam & Associates (SNA) The International Comparative Legal Guide to: Pharmaceutical Advertising 2017 General Chapter: 1 Off-label Use: Current Position in the EU and U.S. – Jackie Mulryne & Mahnu Davar, Arnold & Porter Kaye Scholer LLP 1 Contributing Editor Country Question and Answer Chapters: Ian Dodds-Smith, Arnold & 2 Australia Clayton Utz: Colin Loveday & Greg Williams 7 Porter Kaye Scholer LLP Sales Director 3 Austria Herbst Kinsky Rechtsanwälte GmbH: Dr. Sonja Hebenstreit & Florjan Osmani Dr. Isabel Funk-Leisch 20 Account Director Oliver Smith 4 Belgium Quinz: Olivier Van Obberghen & Joris Beke 33 Sales Support Manager 5 Canada Norton Rose Fulbright Canada LLP: Sara Zborovski & Ian Trimble 43 Paul Mochalski Editor 6 China Jones Day: Chiang Ling Li & Haifeng Huang 53 Caroline Collingwood 7 Denmark Jusmedico Advokatanpartsselskab: Jan Bjerrum Bach & Lone Hertz 63 Senior Editors Suzie Levy, Rachel Williams 8 England & Wales Arnold & Porter Kaye Scholer LLP: Adela Williams & Silvia Valverde 80 Chief Operating Officer Dror Levy 9 Finland Roschier, Attorneys Ltd.: Mikael Segercrantz & Johanna Lilja 95 Group Consulting Editor 10 France LCH Law Compliance Health: Laure Le Calvé & Johanna Benichou 106 Alan Falach Publisher 11 Germany Clifford Chance: Dr.
    [Show full text]
  • Cyclacel Pharmaceuticals, Inc. 2016 Annual Report
    CDK inhibitors: a state-of-the-art class of www.cyclacel.com anticancer medicines CYCLACEL PHARMACEUTICALS, INC. INC. PHARMACEUTICALS, CYCLACEL Cell cycle pioneers: Improving patient lives with orally-available | innovative medicines REPORT ANNUAL 2016 Cyclacel Pharmaceuticals, Inc. | 2016 Annual Report Key Programs: Program Indication Preclinical Phase 1 Phase 2 Phase 3 Marketed Dear Fellow Stockholders, benefit of selective CDK inhibition and has led to great 2016 was a milestone year for our Company as we interest in further development of this class of drugs. completed follow-up in the Phase 3 SEAMLESS study Transcriptional Regulation Cyclacel’s founding scientist, Professor Sir David Lane, in elderly patients with acute myeloid leukemia, or AML. is a globally recognized authority in cell cycle biology SEAMLESS is one of the largest trials conducted in AML. who discovered p53, a key tumor suppressor gene that CYC065 Solid Tumor, We are grateful to the clinical investigators, the patients Phase 1 study malfunctions in about two-thirds of human cancers. Under CDK Inhibitor Blood Cancers and their families for their contributions to completing his guidance, Cyclacel’s drug discovery and development the study. As announced recently, the trial did not reach programs concentrated on the CDK2/9 isoforms, which statistically significant improvement in the primary operate as key components of the p53 pathway. DNA Damage Response endpoint of overall survival for the experimental arm versus an active control arm. However, an improvement Our efforts resulted in bringing two molecules in complete remission rate was observed. In the stratified Sapacitabine Solid Tumors into clinical trials: seliciclib, a first-generation, and and Seliciclib Phase 1/2 study subgroup of patients with low baseline peripheral white CYC065, a second-generation CDK inhibitor.
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    Abbreviated Title: LMB-100 plus SEL-110 Version date: 10/01/18 Abbreviated Title: LMB-100 plus SEL-110 CC Protocol #: 18C0057D Version Date: October 1, 2018 NCT Number: NCT03436732 Title: A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination with SEL-110 in Subjects with Malignant Pleural or Peritoneal Mesothelioma Investigators: NCI Principal Investigator: Raffit Hassan, M.D. A-E Thoracic and GI Malignancies Branch (TGMB), CCR, NCI Building 10, Room 4-5330 9000 Rockville Pike Bethesda, MD 20892 Telephone: 240-760-6232 E-mail: [email protected] NIH Collaborators Ronald Germain, M.D., Ph.D.F, NIAID, NIH Roles A. Obtain information by intervening or interacting with living individuals for research purposes B. Obtaining identifiable private information about living individuals C. Obtaining the voluntary informed consent of individuals to be subjects D. Makes decisions about subject eligibility E. Studying, interpreting, or analyzing identifiable private information or data/specimens for research purposes F. Studying, interpreting, or analyzing coded, linked data or specimens for research purposes G. Some/all research activities performed outside NIH Investigational Agents: Drug Name: LMB-100 (formerly SEL-110 RO6927005) IND Number: 136483 136483 Sponsor: Center for Cancer Research, Center for Cancer Research, NCI, NIH NCI, NIH Manufacturer: F. Hoffmann-La Roche Selecta Biosciences, Inc. Commercial Agents: None 1 Abbreviated Title: LMB-100 plus SEL-110 Version date: 10/01/18 PRÉCIS Background: x LMB-100 and a closely related immunotoxin also targeting mesothelin have been studied in previous Phase 1 clinical studies for mesothelioma and pancreatic cancer. x Results from these studies showed that the majority of patients formed anti-drug-antibodies (ADAs) that neutralized subsequent injection of the product making it ineffective.
    [Show full text]
  • Bro Taf Formulary Since the Most Recent Version of the Formulary Was Posted on the WMIC Website
    Formulary 3rd Edition - Update May 2010 This document includes all drug decisions made by the Medicines & Therapeutics Executive Committee up until April 2010. Dear Colleague This Formulary is the result of collaboration between the Bro Taf Localities Drug & Therapeutics Committee and the two Medicines and Therapeutics Executive Committees for North Bro Taf and Cardiff and the Vale. It has been produced at the Welsh Medicines Information Centre. This Update, produced in May 2010, includes drug decisions made since the last hard copy was printed in 2003. Each chapter is currently undergoing review by clinicians and pharmacists across the local area to enable us to produce a fully revised edition. In the meantime, please email us at the address below if you would like to comment or assist with the review process. Searching the Formulary The quickest way to access information from this pdf document is to use the “edit” option on the toolbar. Drop the menu down to “find on this page” and insert the drug name or other search word. Where possible we have included NICE guidance and CSM warnings. Please refer to the Summary of Product Characteristics for full prescribing information. If you download the formulary from the website, please remember that the formulary on the web will be updated frequently – at least every two months. Hence it will be necessary to download the updated version periodically. Internet access and updates This formulary is constantly being updated. During transition into the main text of the formulary, drugs will appear on an updates list which will be included as a separate section at the beginning of the document (see next page).
    [Show full text]
  • Nomenclature (NOM)
    BRITISH PHARMACOPOEIA COMMISSION Expert Advisory Group (EAG): Nomenclature (NOM) SUMMARY MINUTES A meeting of the Expert Advisory Group on Nomenclature was held at 151 Buckingham Palace Road, Victoria, London SW1W 9SZ on 14 February 2017. Present: Dr J K Aronson (Chairman), Dr M Ahmed, Dr G P Moss, and Mr D Mehta. In attendance: Mr A Evans and Mr L Elanganathan. Apologies for absence were received from Mr Dr R Thorpe and Dr L Tsang. INTRODUCTORY REMARKS Welcome The Chairman welcomed members to the meeting. Declaration of Interests No conflicts of interest were declared. Confidentiality The papers, discussion, and minutes of the meeting were noted to be confidential. I MINUTES 165 The minutes and summary minutes of the meeting held on 10 February 2016 were accepted. II MATTERS ARISING FROM THE MINUTES 166 British Approved Names 2017 This had been published in August 2016. 167 British Approved Names 2017 The review of the Action and use statements for cancer-associated drugs had been completed and included in the publication. III ITEMS FOR THE BRITISH PHARMACOPOEIA 2018 168 Naming of Impurities for BP Monographs A request for advice on naming impurities to be included in new and revised BP monographs that were due to be published in the BP 2018. The names to be used were agreed for inclusion in the monographs for Enalapril Tablets, Indapamide Tablets, Indapamide Prolonged-Release Tablets, Ketoprofen Gel, and Phenindione Tablets EAG NOM: 1 169 Action and Use Statements for BP monographs Hydroquinone The Action and use statement was required for a new BP API monograph to help control a ULM product ‘Tretinoin, Hydrocortisone and Hydroquinone Cream’.
    [Show full text]